Clearside Biomedical, Inc.CLSDNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
Year-over-Year Change
Year-over-year SG&A expense growth
Latest
73.99%
↑ 1267% vs avg
Percentile
P100
Near historical high
Streak
1 qtr
Consecutive growthAccelerating
Average
5.41%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | 73.99% |
| Q2 2025 | -12.32% |
| Q1 2025 | -7.77% |
| Q4 2024 | 7.67% |
| Q3 2024 | -7.57% |
| Q2 2024 | 8.96% |
| Q1 2024 | -4.17% |
| Q4 2023 | 11.76% |
| Q3 2023 | -15.67% |
| Q2 2023 | -0.98% |
| Q1 2023 | -0.35% |
| Q4 2022 | 34.68% |
| Q3 2022 | -15.69% |
| Q2 2022 | -19.27% |
| Q1 2022 | 10.10% |
| Q4 2021 | 11.51% |
| Q3 2021 | 0.00% |
| Q2 2021 | -2.66% |
| Q1 2021 | 9.21% |
| Q4 2020 | 11.58% |
| Q3 2020 | -9.08% |
| Q2 2020 | -16.37% |
| Q1 2020 | -14.47% |
| Q4 2019 | -3.46% |
| Q3 2019 | -24.44% |
| Q2 2019 | 14.14% |
| Q1 2019 | 4.98% |
| Q4 2018 | 7.82% |
| Q3 2018 | 8.76% |
| Q2 2018 | 15.84% |
| Q1 2018 | 25.93% |
| Q4 2017 | 6.22% |
| Q3 2017 | 0.35% |
| Q2 2017 | -14.26% |
| Q1 2017 | 11.71% |
| Q4 2016 | 46.78% |
| Q3 2016 | 67.94% |
| Q2 2016 | -23.80% |
| Q1 2016 | 4.52% |
| Q4 2015 | 14.37% |